D-1334-2022 Class III Terminated

Recalled by Teva Pharmaceuticals USA Inc — Parsippany, NJ

FDA drug recall D-1334-2022 was initiated by Teva Pharmaceuticals USA Inc on Jul 22, 2022 and is designated Class III. Reason for recall: Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification. The recall status is terminated (terminated Apr 12, 2023). Affected quantity: 4162 cartons.

Recall details

Product Type
Drugs
Report Date
Aug 17, 2022
Initiation Date
Jul 22, 2022
Termination Date
Apr 12, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4162 cartons

Product description

Azacitidine for Injection 100mg/vial Lyophilized Powder, Rx Only, Mfd. in Romania By: Sindan Pharma SRL For BluePoint Laboratories, NDC 68001-313-56

Reason for recall

Subpotent Drug - Out of specification (OOS) result obtained during monitoring stability study for Assay. Results below specification.

Distribution pattern

Distributed in Ohio

Code information

Lot: FE22001A, Exp 01/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1334-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1334-2022. Report a data issue: hello@regdatalab.com.